Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

Eriksson, Jan W., Lundkvist, Per, Jansson, Per-Anders, Johansson, Lars, Kvarnström, Mats, Moris, Linda, Miliotis, Tasso, Forsberg, Gun-Britt, Risérus, Ulf, Lind, Lars, Oscarsson, Jan·2018·Diabetologia

DOI 10.1007/s00125-018-4675-2

Cited by (396)

Items 101–200 of 396

Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes
Panagiotis Theofilis, Μarios Sagris, Evangelos K. Oikonomou, Alexios S. Antonopoulos, Gerasimos Siasos, Kostas Tsioufis, Dimitris Tousoulis · 2022 · Diabetes Research and Clinical Practice
The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
Ioana-Cristina Bica, Roxana Adriana Stoica, Teodor Salmen, Andrej Janež, Špela Volčanšek, Djordje S. Popovic, Emir M. Muzurović, Manfredi Rizzo, Anca Pantea Stoian · 2023 · Medicina
Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes
Lars Johansson, Paul D. Hockings, EVA K. JOHNSSON, Nalina Dronamraju, Jill Maaske, Ricardo García‐Sánchez, John P.H. Wilding · 2020 · Diabetes Obesity and Metabolism
Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation
Reem M. Hazem, Ahmed Z. Ibrahim, Dina Adam Ali, Yasser M. Moustafa · 2022 · International Immunopharmacology
Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study
Alfredo Caturano, Raffaele Galiero, Giuseppe Loffredo, Erica Vetrano, Giulia Medicamento, Carlo Acierno, Luca Rinaldi, Aldo Marrone, Teresa Salvatore, Marcellino Monda et al. · 2023 · Biomedicines
Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis
Ke He, Jingxin Li, Xi Wang, Jun Ge, Jingna Sun, Zeng Jing · 2022 · Diabetes Research and Clinical Practice
New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials
Tanawan Kongmalai, Varalak Srinonprasert, Thunyarat Anothaisintawee, Pinkawas Kongmalai, Gareth J. McKay, John Attia, Ammarin Thakkinstian · 2023 · Frontiers in Endocrinology
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, Alexandra C., Das, Sandeep, Kumar, Dhananjay, McKinney, M. Peyton, Cai, Bishuang, Yurdagul, Arif, Rom, Oren · 2023 · Frontiers in Cardiovascular Medicine
Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials
Yunpeng Gu, Lei Sun, Wei Zhang, Tingting Kong, Run Zhou, Yining He, Chaohua Deng, Luping Yang, Jianing Kong, Yutong Chen et al. · 2023 · Frontiers in Pharmacology
Comparison of four non-alcoholic fatty liver disease detection scores in a Caucasian population
Lars Lind, Lars Johansson, Håkan K. Ahlström, Jan W. Eriksson, Anders Olof Larsson, Ulf Risérus, Joel Kullberg, Jan Oscarsson · 2020 · World Journal of Hepatology
Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial
Masato Yoneda, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Takaomi Kessoku, Kento Imajo, Asako Nogami, Masataka Taguri, Hiroyuki Kirikoshi, Satoru Saito et al. · 2022 · Hepatology Communications
Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis
Riccardo Proietti, José Miguel Rivera‐Caravaca, Raquel López‐Gálvez, Stephanie Lucy Harrison, Francisco R. Marín, Paula Underhill, Eduard Shantsila, Garry McDowell, Manlio Vinciguerra, Rhys Davies et al. · 2023 · Journal of Clinical Medicine
Novel Insights into the Genetic Landscape of Nonalcoholic Fatty Liver Disease
Alice Emma Taliento, Marcello Dallio, Alessandro Federico, Daniele Prati, Luca V. C. Valenti · 2019 · International Journal of Environmental Research and Public Health
Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial
Hajime Yamakage, Masashi Tanaka, Takayuki Inoue, Shinji Odori, Toru Kusakabe, Noriko Satoh‐Asahara · 2019 · Journal of Diabetes Investigation
Current and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease
Benoit Smeuninx, Ebru Boslem, Mark Anthony Febbraio · 2020 · Cancers
Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study
Austin G. Stack, David Han, Ronald Goldwater, Susanne A. Johansson, Nalina Dronamraju, Jan Oscarsson, EVA K. JOHNSSON, JOANNA R. PARKINSON, Fredrik Erlandsson · 2020 · The Journal of Clinical Endocrinology & Metabolism
Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study
Hiroshi Tobita, Tomotaka Yazaki, Masatoshi Kataoka, Satoshi Kotani, Akihiko Oka, Tsuyoshi Mishiro, Naoki Oshima, Kousaku Kawashima, Norihisa Ishimura, Kohji Naora et al. · 2020 · Journal of Clinical Biochemistry and Nutrition
Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials
Manjun Deng, Yonghao Wen, Jingxin Yan, Yichen Fan, Zhixin Wang, Ruixia Zhang, Li Ren, Yinggui Ba, Haijiu Wang, Qian Lü et al. · 2023 · BMC Medicine
Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes
Chan Uk Heo, Chang‐Ik Choi · 2019 · Journal of Clinical Medicine
Impact of NAFLD and its pharmacotherapy on lipid profile and CVD
Zhenya Wang, Mao Ye, Xiao‐Jing Zhang, Peng Zhang, Jingjing Cai, Hongliang Li, Zhi‐Gang She · 2022 · Atherosclerosis
Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
Niki Katsiki, Nikolaos Perakakis, Christos Socrates Mantzoros · 2019 · Metabolism
Dapagliflozin Improves Body Fat Patterning, and Hepatic and Pancreatic Fat in Patients With Type 2 Diabetes in North India
Amerta Ghosh, Koel Dutta, Surya Prakash Bhatt, Ritesh Gupta, Kanika Tyagi, Irshad Ahmad Ansari, Vasantha Kumar Venugopal, Harsh Mahajan, Ravindra Mohan Pandey, Shivam Pandey et al. · 2022 · The Journal of Clinical Endocrinology & Metabolism
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
Giulio Marchesini, Elisabetta Bugianesi, Patrizia Burra, Fabio Marra, Luca Miele, Anna Alisi, Piero Vajro, Mario Masarone, Salvatore Petta, Marcello Persico et al. · 2021 · Nutrition Metabolism and Cardiovascular Diseases
Exploring the Role of SGLT2 Inhibitors in Cancer: Mechanisms of Action and Therapeutic Opportunities
Aparamita Pandey, Martín Alcaraz, Pasquale Saggese, Adriana Soto, Estefany Gomez, Shreya Jaldu, Jane Yanagawa, Claudio Scafoglio · 2025 · Cancers
Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease
Yajie Fu, Yanzhi Zhou, Linhu Shen, Xuewen Li, Haorui Zhang, Yeqi Cui, Ke Zhang, Weiguo Li, Weidong Chen, Shizhen Zhao et al. · 2022 · Frontiers in Pharmacology
Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease
Aikaterini Andreadi, Saverio Muscoli, Rojin Tajmir, Marco Meloni, Carolina Muscoli, Sara Ilari, Vincenzo Mollace, David Della‐Morte, Alfonso Bellia, Nicola Di Daniele et al. · 2023 · International Journal of Molecular Sciences
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
Maria Zachou, Pagona Flevari, Narjes Nasiri Ansari, Constantinos Varytimiadis, Evangelos Kalaitzakis, Eva N. Kassi, Θεόδωρος Ανδρουτσάκος · 2023 · European Journal of Clinical Pharmacology
Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes
Siham Abdelgani, Ahmed Khattab, John M. Adams, Gozde Baskoy, Marissa Brown, Geoff Clarke, Olga Larvenenko, Ralph Anthony DeFronzo, Muhammad A Abdul‐Ghani · 2024 · Diabetes Care
The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
Leonardo Buttice, Maryam Ghani, Janahan Suthakar, Sathyan Gnanalingham, Elliott J. Carande, Brett W. C. Kennedy, Alex Pitcher, James H.P. Gamble, Mahmood Ahmad, Andrew Lewis et al. · 2024 · Diabetes Obesity and Metabolism
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
Giulio Marchesini, Elisabetta Bugianesi, Patrizia Burra, Fabio Marra, Luca Miele, Anna Alisi, Piero Vajro, Mario Masarone, Salvatore Petta, Marcello Persico et al. · 2021 · Digestive and Liver Disease
NAFLD in type 2 diabetes mellitus: Still many challenging questions
Simona Cernea, Itamar Raz · 2020 · Diabetes/Metabolism Research and Reviews
Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases
Waihong Chung, Kittichai Promrat, Jack R. Wands · 2020 · World Journal of Hepatology
Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management
Hersh Shroff, Lisa B. VanWagner · 2020 · Current Hepatology Reports
Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition
Peter S. Wolf, Paul Fellinger, Lorenz Pfleger, Hannes Beiglböck, Patrik Krumpolec, Chiara Barbieri, Amalia Gastaldelli, Jürgen Harreiter, Matthäus Metz, Thomas Scherer et al. · 2020 · Diabetes Care
Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis
Chien‐Yu Lin, Pratik Adhikary, Kun Cheng · 2021 · Advanced Drug Delivery Reviews
Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials
Lei Sun, Chaohua Deng, Yunpeng Gu, Yining He, Luping Yang, Junping Shi · 2022 · Clinics and Research in Hepatology and Gastroenterology
Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: A mechanism review
Lingli Xie, Xia Wenfang · 2022 · Life Sciences
PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review
Joost Boeckmans, Alexandra Gatzios, Jörn Markus Schattenberg, Ger H. Koek, Robim Marcelino Rodrigues, Tamara Vanhaecke · 2023 · Liver International
Updated S2k clinical practice guideline on non-alcoholic fatty liver disease (NAFLD) issued by the German society of gastroenterology, digestive and metabolic diseases (DGVS)–April 2022–AWMF Registration No.: 021–025
Authors, Collaborators: · 2022 · Zeitschrift für Gastroenterologie
PNPLA3 I148M Interacts With Environmental Triggers to Cause Human Disease
Elizabeth K. Speliotes, Carolin Victoria Schneider · 2024 · Liver International
Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
Evangelia S. Makri, Antonis Goulas, Stergios A. Pοlyzos · 2021 · European Journal of Pharmacology
Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis
Peipei Zhou, Ying Tan, Zhenning Hao, Weilong Xu, Xiqiao Zhou, Jiangyi Yu · 2023 · Frontiers in Endocrinology
Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis
Jingxuan Lian, Jianfang Fu · 2021 · Frontiers in Endocrinology
Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus
Enxiang Zhang, Yang Zhao, Hongbo Hu · 2021 · Hepatology Communications
Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: A systematic review and meta-analysis of randomized controlled trials
Mario Alberto Simental-Mendía, Adriana Sánchez‐García, Mariana Rodríguez-Ramírez, Luis E. Simental‐Mendía · 2020 · Pharmacological Research
Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Luo, Qian, Wei, Ruojun, Cai, Yuzi, Zhao, Qihan, Liu, Yuning, Liu, Wei Jing · 2022 · Frontiers in Medicine
The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
Michail Koutentakis, Jakub Kuciński, Damian Świeczkowski, Stanisław Surma, Krzysztof Jerzy Filipiak, Aleksandra Gąsecka · 2023 · Journal of Cardiovascular Development and Disease
Metabolic reprogramming of immune cells in MASH
Chuhan Ma, Shuyue Wang, Bingning Dong, Yu Tian · 2025 · Hepatology
Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease
Fasiha Kanwal, Fernando Bril, Vincent Wai‐Sun Wong, Leon A. Adams, Kim M. Pfotenhauer, NEIL SKOLNIK, Eugene E. Wright, Robert H. Eckel, Mazen Noureddin, Rohit Seth Loomba et al. · 2026 · Gastroenterology
Meta‐analysis of the effects of sodium glucose cotransporter 2 inhibitors in non‐alcoholic fatty liver disease patients with type 2 diabetes
Binayak Sinha, Debasis Datta, Samit Ghosal · 2020 · JGH Open
“The pharmacological profile of SGLT2 inhibitors: Focus on mechanistic aspects and pharmacogenomics”
Prabhsimran Kaur, Bidwan Sekhar Behera, Sandeep Singh, Anjana Munshi · 2021 · European Journal of Pharmacology
Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence
Koichi Yabiku · 2021 · Frontiers in Endocrinology
SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
Naser Eddin Gharaibeh, Marie-Noel Rahhal, Leili Rahimi, Faramarz Ismail‐Beigi · 2019 · Diabetes Metabolic Syndrome and Obesity
Association of sodium‐glucose cotransporter 2 inhibitors with risk of incident dementia and all‐cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks
Pai, Yen‐Wei, Chen, I‐Chieh, Lin, Jun‐Fu, Chen, Xiao‐Hui, Chen, Hsin‐Hua, Chang, Ming‐Hong, Huang, Jin‐An, Lin, Ching‐Heng · 2024 · Diabetes, Obesity and Metabolism
Impact of omega-3 fatty acids supplementation on the gene expression of peroxisome proliferator activated receptors-γ, α and fibroblast growth factor-21 serum levels in patients with various presentation of metabolic conditions: a GRADE assessed systematic review and dose–response meta-analysis of clinical trials
Amirhossein Ramezani Ahmadi, Fatemeh Shirani, Behnaz Abiri, Mansour Siavash, Sasan Haghighi, Mojtaba Akbari · 2023 · Frontiers in Nutrition
2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes
Amélio F. Godoy‐Matos, Cynthia Melissa Valério, Wellington Santana da Silva Júnior, João Marcello de Araújo Neto, Marcello Casaccia Bertoluci · 2024 · Diabetology & Metabolic Syndrome
Pharmacological treatment options for metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review
Laura A. M. Konings, Lorena Miguelañez Matute, Anna M P Boeren, Inge A. T. van de Luitgaarden, Femme Dirksmeier-Harinck, Robert Jacobus de Knegt, Maarten E. Tushuizen, Diederick E. Grobbee, Adriaan Georgius Holleboom, Manuel Castro Cabezas · 2025 · European Journal of Clinical Investigation
The impact of sodium glucose co‐transporter 2 inhibitors on non‐alcoholic fatty liver disease
Lampros Chrysavgis, Alkistis‐Maria Papatheodoridi, Antonios Chatzigeorgiou, Εvangelos Cholongitas · 2020 · Journal of Gastroenterology and Hepatology
Effects of Epeleuton, a Novel Synthetic Second‐Generation n‐3 Fatty Acid, on Non‐Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers
John Climax, Philip Noel Newsome, Moayed Hamza, Markus Weissbach, David Coughlan, Naveed A. Sattar, Darren K. McGuire, Deepak L. Bhatt · 2020 · Journal of the American Heart Association
Novel glucose-lowering drugs for non-alcoholic fatty liver disease
Zuodi Fu, Xiaoling Cai, Wenjia Yang, Ming-Ming Zhao, Ran Li, Yufeng Li · 2021 · World Journal of Diabetes
The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis
Man-Qiu Mo, Zichun Huang, Yuzhen Liang, Yunhua Liao, Ning Xia · 2021 · Digestive and Liver Disease
Lower Risks of New-Onset Hepatocellular Carcinoma in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors Versus DPP4 Inhibitors
Oscar Hou In Chou, Jing Ning, Raymond Ngai Chiu Chan, Cheuk To Chung, Helen Ye Rim Huang, Kenrick Ng, Edward Christopher Dee, Sharen Lee, Apichat Kaewdech, Ariel Ka-Man Chow et al. · 2024 · Journal of the National Comprehensive Cancer Network
Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Da Zhou, Jian‐Gao Fan · 2024 · Chinese Medical Journal
A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Yvelise Ferro, Roberta Pujia, Elisa Mazza, Lidia Lascala, Oscar Lodari, Samantha Maurotti, Arturo Pujia, Tiziana Montalcini · 2022 · Journal of Translational Medicine
Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors
Panagiotis Theofilis, Evangelos K. Oikonomou, Konstantinos P Tsioufis, Dimitris Tousoulis · 2023 · Life
Effect of SGLT-2 Inhibitors on Non-alcoholic Fatty Liver Disease among Patients with Type 2 Diabetes Mellitus: Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials
Kai Wei Lee, Navin Kumar Devaraj, Siew Mooi Ching, Sajesh Kalkandi Veettil, Fan Kee Hoo, Inas Deuraseh, Man Jun Soo · 2021 · Oman Medical Journal
Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease
Emily E. Brown, Theresa Hydes, A. Hamid, Daniel James Cuthbertson · 2021 · Clinical Therapeutics
Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management
Maja Cigrovski Berković, Lucija Virović-Jukić, Ines Bilić-Čurčić, Anna Mrzljak · 2020 · World Journal of Gastroenterology
The Plasma Metabolomic Profile is Differently Associated with Liver Fat, Visceral Adipose Tissue, and Pancreatic Fat
Lars Lind, Samira Salihović, Ulf Risérus, Joel Kullberg, Lars Johansson, Håkan K. Ahlström, Jan W. Eriksson, Jan Oscarsson · 2020 · The Journal of Clinical Endocrinology & Metabolism
Meta‐analysis of the effect of sodium–glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non‐alcoholic fatty liver disease
Tiantian Song, Shuchun Chen, Hang Zhao, Fei Wang, Huan Song, Dongliang Tian, Qiwen Yang, Licui Qi · 2021 · Hepatology Research
The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis
Hongsheng Li, Yanli Hou, Wenyong Xin, Lina Ding, Ying Yang, Yikun Zhang, Wenqi Wu, Zhibin Wang, Wenyu Ding · 2025 · Pharmacological Research
The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Chan‐Hee Jung, Ji‐Oh Mok · 2019 · Journal of Obesity & Metabolic Syndrome
Perirenal Adiposity and Other Excessive Intra- and Peri-Organ Fat Depots: What Is the Connection?
Niki Katsiki, George Dimitriadis, Dimitri P. Mikhailidis · 2019 · Angiology
Mechanisms, screening modalities and treatment options for individuals with non‐alcoholic fatty liver disease and type 2 diabetes
Hydes, T. J., Summers, N., Brown, E., Alam, U., Thomaides‐Brears, H., Wilding, J. P. H., Cuthbertson, D. J. · 2020 · Diabetic Medicine
Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis
Komolafe, Oluyemi, Buzzetti, Elena, Linden, Audrey, Best, Lawrence MJ, Madden, Angela M, Roberts, Danielle, Chase, Thomas JG, Fritche, Dominic, Freeman, Suzanne C, Cooper, Nicola J et al. · 2021 · Cochrane Database of Systematic Reviews
Effects of sodium-glucose cotransporter 2 inhibitor (dapagliflozin) on food intake and plasma fibroblast growth factor 21 levels in type 2 diabetes patients
Rieko Kosugi, Eiji Nakatani, Kensuke Okamoto, Saeko Aoshima, Hidekazu Arai, Tatsuhide Inoue · 2019 · Endocrine Journal
Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Won Euh, Soo Kyung Lim, Jin‐Wook Kim · 2021 · Frontiers in Endocrinology
N-3 Polyunsaturated Fatty Acids and Their Lipid Mediators as A Potential Immune–Nutritional Intervention: A Molecular and Clinical View in Hepatic Disease and Other Non-Communicable Illnesses
Francisca Herrera Vielma, Rodrigo Valenzuela, Luis Alberto Videla, Jessica Zúñiga‐Hernández · 2021 · Nutrients
Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease
Fu‐Shun Yen, Chih‐Cheng Hsu, James Cheng‐Chung Wei, Ming‐Chih Hou, Chii‐Min Hwu · 2022 · Frontiers in Medicine
Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes
Rosemarie Lajara · 2019 · Postgraduate Medicine
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO) · 2021 · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity
Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Mohammad Shafi Kuchay, Khalid Jamal Farooqui, Sunil Kumar Mishra, Ambrish Mithal · 2020 · Advances in experimental medicine and biology
SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
Rong Xu, Difei Lian, Yan Xie, Zhilei Chen, Yan Wang, Lin Mu, Yuan Wang, Baoyu Zhang · 2023 · Frontiers in Bioscience-Landmark
Non-alcoholic fatty liver disease: Dietary and nutraceutical approaches
Ludovica Cogorno, Elena Formisano, Andrea Vignati, Amalia Prigione, Antonio Tramacere, Consuelo Borgarelli, Samir Giuseppe Sukkar, Livia Pisciotta · 2023 · Liver Research
Omega-3 polyunsaturated fatty acids and nonalcoholic fatty liver disease in adults: A meta-analysis of randomized controlled trials
Su Jin Kim, Su Hwan Cho, Jae Moon Yun · 2025 · Clinical Nutrition
Dapagliflozin ameliorates hepatic steatosis via suppressing LXRα-mediated synthesis of lipids and bile acids
Zijie Jin, Ruotong Yin, Yan Yuan, Chen Zheng, Peng Zhang, Yalin Wang, Hongbo Weng · 2024 · Biochemical Pharmacology
Liver and cardiovascular disease outcomes in metabolic syndrome and diabetic populations: Bi-directional opportunities to multiply preventive strategies
Alhussain Yasin, Madison Nguyen, Angad Sidhu, Priyanka Majety, Jared Alexander Spitz, Amon Asgharpour, Mohammad Shadab Siddiqui, Laurence S. Sperling, Arshed Ali Quyyumi, Anurag Mehta · 2024 · Diabetes Research and Clinical Practice
Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care
Laurence J. Dobbie, Mohamed Kassab, Andrew Davison, Pete Grace, Daniel James Cuthbertson, Theresa Hydes · 2021 · Journal of Clinical Medicine
Non-Alcoholic Fatty Liver Disease (NAFLD) Management in the Community
Y.B. Park, Kyung Soo Ko, Byoung Doo Rhee · 2025 · International Journal of Molecular Sciences
Dapagliflozin alleviates arsenic trioxide-induced hepatic injury in rats via modulating PI3K/AkT/mTOR, STAT3/SOCS3/p53/MDM2 signaling pathways and miRNA-21, miRNA-122 expression
Basel A. Abdel‐Wahab, Ehab A. M. El‐Shoura, Mohammed Shafiuddin Habeeb, Dalia K. Zaafar · 2023 · International Immunopharmacology
Hypogonadism and nonalcoholic fatty liver disease
Kasiani Papadimitriou, Athanasios C. Mousiolis, Gesthimani Mintziori, Christina Tarenidou, Stergios A. Pοlyzos, Dimitrios G. Goulis · 2024 · Endocrine
Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials
Maria‐Styliani Kalogirou, Dimitrios Patoulias, Anna‐Bettina Haidich, Evangelos A. Akriviadis, Emmanouil Sinakos · 2020 · Clinics and Research in Hepatology and Gastroenterology
Impact of PNPLA3 in Lean Individuals and in Cryptogenic Steatotic Liver Disease
Yuya Seko, Huapeng Lin, Vincent Wai‐Sun Wong, Takeshi Okanoue · 2024 · Liver International
Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis
Chen Ding, Yaxin Tang, Wenqiang Zhu, Piaopiao Huang, Pingan Lian, Juanli Ran, Xiansheng Huang · 2022 · Acta Diabetologica
Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
Silvina Gallo, Roberto A. Calle, Steven G. Terra, Annpey Pong, Lisa C. Tarasenko, Annaswamy Raji · 2020 · Diabetes Therapy
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association
Atul Deep Bali, Akiva Rosenzveig, William H. Frishman, Wilbert S. Aronow · 2023 · Cardiology in Review
Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes
Georgios Tsamos, Dimitra Vasdeki, Theocharis Koufakis, Vasiliki Michou, Kali Makedou, Georgios Tzimagiorgis · 2023 · Metabolites
Comparison of SGLT2 inhibitors vs. DPP4 inhibitors for patients with metabolic dysfunction associated fatty liver disease and diabetes mellitus
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, R. Ohno, Isao Yokota, Katsuhito Fujiu, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Koichi Node et al. · 2023 · Journal of Endocrinological Investigation
Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter Protein-2 Inhibitors on Treating Metabolic Dysfunction-Associated Steatotic Liver Disease or Metabolic Dysfunction-Associated Steatohepatitis: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials
Ruhan Xu, Bo Liu, Xianghai Zhou · 2024 · Endocrine Practice
Role of anti-diabetic medications in the management of MASLD
Scott D. Isaacs, Fiona V Farrelly, Paul Brennan · 2025 · Frontline Gastroenterology